Please provide your email address to receive an email when new articles are posted on . SEATTLE — The effects of aflibercept treatment in the three arms of the PULSAR study were not affected by ...
Assessment of Rare Cancers and Sarcoma Policy and Sarcoma Drug Approvals in Latin America: A Report From the LACOG Sarcoma Group We enrolled patients with stage I-IV breast cancer at Princess Marina ...
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results